Physician profile
Lesa Kerley
NPI 1194121624
$2,484.10
in general payments reported to CMS, 2019-2025
31 companies · $37.21 in 2025
The $37.21 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.41 · 2023: $1,591 · 2024: $843 · 2025: $37.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,686 · Education: $785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,685.94 |
| Education | $784.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $616.83 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Janssen Biotech, INC. | $345.70 | 2023-2024 | Darzalex, Erleada, Imbruvica |
| Incyte Corporation | $183.55 | 2023-2024 | Jakafi, Pemazyre, Monjuvi |
| Seagen INC. | $144.62 | 2023 | Tukysa, Adcetris |
| Novartis Pharmaceuticals Corporation | $125.19 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $113.63 | 2023-2024 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $79.98 | 2023-2024 | Injectafer, Enhertu |
| Pfizer INC. | $75.84 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $72.98 | 2023-2024 | Enhertu, Tagrisso, Imfinzi |
| Exelixis INC. | $71.11 | 2023-2024 | Cabometyx |
| Genentech USA, INC. | $64.90 | 2023-2024 | Kadcyla, Perjeta, Phesgo |
| Regeneron Healthcare Solutions, INC. | $64.37 | 2023-2024 | Libtayo |
| Mirati Therapeutics, INC. | $54.28 | 2023-2024 | Krazati |
| Jazz Pharmaceuticals INC. | $44.79 | 2024 | |
| Array Biopharma INC | $41.71 | 2023-2024 | Mektovi, Braftovi, Lorbrena |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Morphosys, US INC. | $39.16 | 2023 | Monjuvi |
| Eisai INC. | $35.17 | 2023 | |
| Celgene Corporation | $33.21 | 2023-2024 | Reblozyl, Opdualag |
| Taiho Oncology, INC. | $30.72 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $27.78 | 2023-2024 | Opdualag, Opdivo |
| Puma Biotechnology, INC. | $27.01 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $23.73 | 2023 | Truxima |
| Tersera Therapeutics LLC | $23.38 | 2023 | Zoladex |
| Pharmacosmos Therapeutics INC. | $22.41 | 2025 | Monoferric |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.21 | 2023 | Gilotrif |
| Ipsen Biopharmaceuticals, INC | $21.03 | 2024 | Onivyde, Somatuline Depot |
| Alexion Pharmaceuticals, INC. | $19.37 | 2024 | Ultomiris |
| Kyowa Kirin, INC. | $16.71 | 2023 | Poteligeo |
| Grifols USA, LLC | $15.52 | 2024 | Gamunex-C |
| Genzyme Corporation | $14.80 | 2025 | |
| Amgen INC. | $13.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesa Kerley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.